• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

    2018-12-07 06:21:40JingWangYizhuoZhaoQimingWangLiZhangJianhuaShiZhehaiWangYingChengJianxingHeYuankaiShiHaoYuYangZhaoWeiqiangChenYiLuoXiuwenWangKejunNanFaguangJinJianDongBaolanLiZhujunLiuBaohuiHanKaiLi
    Cancer Biology & Medicine 2018年4期

    Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He,Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin,Jian Dong, Baolan Li, Zhujun Liu, Baohui Han, Kai Li

    1Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China;2Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai 230030, China; 3Department of Medical Oncology,Henan Province Tumor Hospital, Zhengzhou 450008, China; 4Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730 China; 5Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276001, China;6Department of Internal Medicine, Shandong Cancer Hospital, Jinan 250117, China; 7Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China; 8Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 9Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China; 10Department of Biostatistics, School of Public Health, Nanjing Medical University,Nanjing 210029, China; 11Department of Respiratory Medicine, Lanzhou Military General Hospital, Lanzhou 730050, China;12Department of Head and Neck Oncology, Hunan Cancer Hospital, Changsha 220633, China; 13Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan 250000, China; 14Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; 15Department of Respiratory and Critical Diseases, Tang Du Hospital, Xi'an 710038, China; 16Department of Oncology, Yunnan Cancer Hospital, Kunming 650032, China; 17General Department, Capital Medical University Beijing Chest Hospital, Beijing 101149, China

    ABSTRACT Objective: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-angiogenetic activities. A phase III trial has shown that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC), who presented with progressive disease or intolerance after standard chemotherapy. This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods: Data were collected from March 2015 to January 2017 from a randomized, double-blind, placebo-controlled,multicenter, phase III trial of anlotinib (ALTER0303). A total of 437 patients were enrolled and randomly allocated (2:1) to the anlotinib and placebo groups. Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS. Cox proportional hazards model was adopted for multivariate prognostic analysis.Results: Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS. Meanwhile, elevated thyroid-stimulating hormone, blood glucose, and triglyceride levels; hypertension; and hand–foot syndrome were independent protective factors of PFS. High posttherapeutic peripheral blood granulocyte/lymphocyte ratio, an Eastern Cooperative Oncology Group (ECOG) score ≥ 2, and the sum of the maximal target lesion length at baseline were independent risk factors of OS, and hypertriglyceridemia was an independent protective factor of OS.Conclusions: This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC, and the baseline characteristics of the therapeutically dominant populations were then identified.

    KEYWORDS Non-small cell lung cancer; anlotinib; third- or further-line therapy; prognostic factor analysis

    Introduction

    Non-small cell lung cancer (NSCLC) accounted for the highest morbidity and mortality rates among all other malignancies in recent years. Patients who received chemotherapy have a median survival of < 1 year, and those with driver gene mutations who receive targeted therapies also developed resistance after 1 year of treatment. The National Comprehensive Cancer Network guidelines provided regulations only for the first- and second-line regimens. Therefore, the primary focus of research is to help patients who are resistant to third- or further-line regimens recover and to lengthen their survival. Phase II1and III trials of the novel vascular-targeting agent anlotinib have shown that progression-free survival (PFS) and overall survival (OS)significantly improved in the anlotinib group than in the placebo group. However, this conclusion was only based on the general data of the patients. Thus, we evaluated the major factors that affected both the PFS and OS of the patients from the phase III trial with the hope of determining the therapeutically dominant populations and discovering an optimal therapeutic regimen for individuals with advanced refractory NSCLC.

    Materials and methods

    General data

    Between March 2015 and August 2016, 437 patients were enrolled from 31 research centers in China, and the data of the patients from March 2015 to January 2017 were collected.The major inclusion criteria were as follows: 1) patients who were pathologically diagnosed with stage III B/IV advanced NSCLC and had measurable nidus; 2) those who have progressive disease after receiving at least two standard systematic chemotherapeutic regimens or those who could not tolerate the toxicity of these treatments; 3) those who were negative for epidermal growth factor receptor (EGFR)and anaplastic lymphoma kinase (ALK) and can provide detectable specimens from tumor tissues or the hydrothorax for gene detection before participating in the study or those who were positive for EGFR and ALK and presented with progressive disease (PD) or intolerable adverse effects after treatment with relative targeted drugs; and 4) those with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0–1 points. All patients must sign the informed consent form prior to enrollment. The present trial was approved by the corresponding ethics committees of our institution and is registered in ClinicalTrials.gov (registration number: NCT02388919).

    Methods of treatment

    Patients were randomized to receive anlotinib or placebo in a 2 : 1 ratio. The medication was administered from days 1 to 14 in a 21-day cycle, and the initial dose of anlotinib was 12 mg oral administered once daily.

    Efficacy evaluation

    Objective efficacy measures were evaluated using the guidelines of the response evaluation criteria in solid tumors version 1.1.

    OS was defined as the duration between randomization and death from any cause. For patients who were considered lost to follow-up, the date of the last follow-up visit was calculated equally as the date of death.

    PFS was defined as the duration between randomization and objective tumor progression or death.

    For patients who had complete response (CR) or partial response (PR) and stable disease (SD) based on the efficacy evaluation, tumor nidi should be re-examined 4 and 6–8 weeks after the initial efficacy evaluation to identify the efficacy until disease progression (DP).

    Disease control rate was defined as the percentage of patients who can be evaluated and achieved CR, PR, and SD for at least 4 weeks.

    Record of adverse events

    Patients were regularly followed-up as per the trial protocol,and each observation index was recorded accordingly.Adverse events were assessed on the basis of the guidelines of the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0), and the most severe post-treatment adverse events in each therapeutic cycle were statistically analyzed.

    Statistical analysis

    All analyses were performed using the SAS 9.4 software (SAS Institute Inc., Cary, NC, the USA). Demographic data and baseline disease characteristics were presented as categorical variables. Univariate and multivariate Cox proportional hazards models were adopted to analyze the influential factors associated with PFS and OS. To establish the final model, a list of potential variables were firstly provided based on prior information regarding their clinical relevance, and the best subset method was then utilized to select the final model according to Chi-square statistics and clinical relevance. Variables that showed significance in the multivariate analysis were stratified, whereas the median OS or PFS were reported. Parameters with obvious clinical reference values, such as blood cholesterol and low-density lipoprotein (LDL) cholesterol level, were classified based on clinical reference values; meanwhile, parameters without obvious clinical reference values, such as pre-randomization maximal target lesion length and post-treatment granulocyte/lymphocyte ratio, were grouped using the cutoff values that were calculated using the receiver operating characteristic (ROC) curves. Cutoff values were obtained using survival status (dead or alive) at the end of follow-up and were considered as outcome variables. The value of the predictive variable with maximal sensitivity + sepecificity-1 was selected as the cutoff point. The between-group comparisons of OS and PFS were analyzed using t-test. For all analyses, a P value < 0.05 was considered statistically significant.

    Results

    Baseline data and efficacy

    In the present study, 437 and 377 patients were included in the full analysis set (FAS) and per protocol set (PPS),respectively, and 256 and 121 patients were classified into the anlotinib and placebo groups, respectively.

    By the end of the follow-up period (January 06, 2017) with a median follow-up period of 9.24 months for the anlotinib group and 7.33 months for the placebo group, the median PFS were 5.37 months [95% confidence interval (CI):4.40–5.63] for the anlotinib group and 1.40 months (95% CI:1.07–1.50) for the placebo group, which indicated statistically significant differences (P < 0.0001). Compared to the placebo group, the anlotinib group had an extended duration for the control of advanced NSCLC by 3.97 months and a lower risk for DP by 75%, which indicated statistically significant differences [hazard ratio (HR) = 0.25, 95% CI: 0.19–0.31, P <0.0001]. The OS were 9.63 months (95% CI: 8.17–10.60 ) and 6.30 months (95% CI: 5.00–8.10) in the anlotinib and placebo groups, respectively. Compared to that of the placebo group, the median OS of the anlotinib group improved by 3.33 months and their risk for mortality decreased by 32%. This result showed statistically significant differences (HR = 0.68, 95% CI: 0.54–0.87, P = 0.0018). In addition, after the data cutoff, we continued the follow-up for OS until May 2017, and further survival analysis showed a similar result. That is, a median OS of 9.60 months (95% CI:8.4–10.6) was obtained, and it was significantly (P = 0.0018)longer in the anlotinib group than in the placebo group with an improvement of 3.30 months. The baseline data of the 256 patients from the anlotinib group are listed in Table 1.

    Table 1 Clinicopathological data of 256 patients in the anlotinib group

    Univariate and multivariate analyses of efficacy

    Based on the primary observation parameters of the current trial and previous reports, we preliminarily selected 43 variables that might affect prognosis, and Kaplan–Meier univariate analysis and log-rank test were then conducted to assess the correlations between the variables and PFS or OS.The factors were categorized as follows: 1) patient factors,including sex, age, ECOG score at the end of the medication,blood granulocyte/lymphocyte ratio, changes in laboratory parameters before and after treatment, and occurrence of the most severe adverse events; 2) therapeutic factors, such as pre-randomization lines and duration of treatment and content of therapeutic regimens; and 3) tumor factors, such as sum of pre-randomized maximal target lesion length,clinical stage, pathological type, etc.

    Since the pre-randomization ECOG score of the trial was limited between 0 and 1 point and the post-treatment body performance of some patients worsened, which resulted in a higher ECOG score of 0–3 points in the univariate analysis,the patients were stratified into 0–1-point subgroup and 2–3-point subgroup. The cutoff value for the stratification of age was 60 years. Adverse events were defined on the basis of the definitions of CTCAE 4.0 (hand–foot syndrome, oral mucositis, and rash), and hypertension was defined as blood pressure ≥ 140/90 mmHg.

    Classification of the cutoff values of the laboratory parameters was based on their respective clinical reference values: hypertriglyceridemia was defined as a triglyceride level > 1.7 mmol/L, hypercholesterolemia was defined as cholesterol level > 5.17 mmol/L, elevated alkaline phosphatase (ALP) level was defined as an ALP level> 135 U/L, hyperglycemia was defined as blood sugar level> 5.9 mmol/L, hypomagnesemia was defined as blood magnesium level < 0.66 mmol/L, hypocalcemia was defined as serum calcium level < 2.10 mmol/L, hyponatremia was defined as blood sodium level <137 mmol/L, hyper-lowdensity lipoproteinemia was defined as lipoprotein level> 3.1 mmol/L, elevated thyroid-stimulating hormone (TSH)was defined as TSH level > 4.85 mIU/L, and prolonged QT interval on electrocardiogram (ECG) was defined as QT interval > 480 ms.

    For variables without a reference value, the ROC curves were used to analyze and determine the cutoff values with significant differences in OS, which is the primary endpoint of the trial. The cutoff value of pre-randomization maximal target lesion length was 72 mm, the sensitivity was 0.5283,the specificity was 0.7368, and the area under the curve was 0.6600. The cutoff value of post-treatment granulocyte/lymphocyte ratio was 3.10, the sensitivity was 0.6689, the specificity was 0.6989, and the area under the curve was 0.7089.

    Factors with statistically significant differences in the univariate analysis are listed in Table 2. However, variables without statistically significant correlations with PFS or OS are not shown.

    The SAS statistical software was utilized to select 15 combinations of variables using the fitting curve. The Cox model was then used to analyze the combination of variables,and results showed that the following variables had statistically significant differences (Table 3). However, the variables without statistically significant correlations with PFS or OS are not shown.

    Results of the multivariate analysis indicated that high post-treatment granulocyte/lymphocyte ratio and elevated ALP levels were considered independent risk factors of PFS,whereas hypertension, hand–foot syndrome (hand–foot skin reaction), hyperglycemia, hypertriglyceridemia, and elevated TSH levels were independent protective factors of PFS. Posttreatment ECOG score ≥ 2, high post-treatment peripheral blood granulocyte/lymphocyte ratio, and the sum of prerandomization maximal target lesion length were considered independent risk factors of OS, whereas hypertriglyceridemia was an independent protective factor of OS.

    To further evaluate the clinical significance of the cutoff values, stratified median PFS and OS were reported for each variable, which was statistically significant in the multivariate model according to these cutoff values(Table 4).

    Discussion

    Anlotinib is a self-developed multitargeted inhibitor designed to inhibit vascular endothelial growth factor receptor-2(VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor-1 (FGFR1), FGFR2, FGFR3, platelet-derived growth factor receptor-α (PDGFRα), PDGFRβ, c-KIT, c-Met, and EGFR in China2,3. Compared with similar target agents, such as sorafenib4, anlotinib targets the tumor vascular microenvironment and the responsible genes and signaling pathways associated with malignant biological behaviors,such as cancer cell growth, invasion, and metastasis.Therefore, it is considered to be a multitargeted, dualdimension, comprehensive anti-tumor drug that can control tumor resistance after a single chemotherapy or targeted drug treatment. In this trial, anlotinib was used in patients with advanced NSCLC who developed resistance after at least two therapeutic regimens. Results revealed a median PFS of 5.37 months and a median OS of 9.63 months, which lower therisks for DP by 75% (HR = 0.25, 95% CI: 0.19–0.31, P <0.0001) and 32% (HR = 0.68, 95% CI: 0.54–0.87, P =0.0018), respectively, compared to the placebo group. The PFS and OS of patients with advanced NSCLC (squamous cell carcinoma and adenocarcinoma) receiving classic second-line chemotherapeutic regimens are approximately 2.5 and 7 months, respectively5. Patients with adenocarcinoma who received second-line therapies based on pemetrexed had a median OS of 8.3 months6, whereas patients with adenocarcinoma who are taking tyrosine kinase inhibitor (TKI; Tarceva) as the second-line therapy had a median OS of 7.8 months7. However, data about the efficacy of third-line therapy that is supported by class II evidence or higher recommendations are still limited. In this trial, we used anlotinib as the third-line salvage regimen for patients who are resistant to treatment or those who cannot tolerate toxicities, and higher PFS and OS rates were observed in patients receiving these regimens than in those receiving

    previous standard second-line regimens. This might be due to the simultaneous inhibition of tumor and its angiogenesis and blockage of multiple key receptors, which effectively prevented tumor growth-related signaling. However, all enrolled patients who presented with advance cancer and refractory lung malignancies (including squamous cell cancer, adenocarcinoma, and large cell carcinoma but not limited to adenocarcinoma only) were significantly resistant to all the drugs compared with those with tumors who were receiving second- and inferior-line therapies. Hence, we conducted a stratified analysis to assess the factors that affect efficacy to determine therapeutically dominant populations and prevent the use of ineffective medications.

    Table 2 Results of the prognostic factor analysis of patients from the anlotinib group (univariate analysis)

    Table 3 Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)

    Results of the univariate analysis showed that 13 factors affected PFS, and they were primarily patient factors and adverse events (see table 2). No therapeutic factors significantly affected PFS. A total of 11 factors affect OS, and seven factors affected PFS. They were patient factors and tumor factors (Table 2), no therapeutic factors were involved. Based on the abovementioned results and previous reports, several parameters that affect the prognosis were introduced into the multivariate Cox model. The results showed that the post-treatment adverse events of hypertension and hand–foot syndrome, blood glucose level >5.9 mmol/L, triglyceride level > 1.7 mmol/L, and TSH level >4.85 mmol/L were considered independent protective factors of OS, whereas post-treatment granulocyte/lymphocyte ratio> 3.10 and ALP level > 135 U/L were considered independent risk factors of PFS. Post-treatment triglyceride level > 1.7 mmol/L was an independent protective factor for OS,whereas a post-treatment ECOG score of 2–3, post-treatment granulocyte/lymphocyte ratio > 3.10, and maximal target lesion length> 72 mm were independent risk factors for OS. To assess the practical cutoff values clinically, we adopted the ROC curve to analyze the cutoff values showing the most significant differences in PFS and OS. After comparing with the reference values used for clinical practice, the cutoff values presenting the near coincidence in each normal upper laboratory indexes and changes in blood pressure were almost similar to the normal upper limits of the corresponding clinical reference ranges. Therefore, the cutoff values of the factors in the current study, which were estimated via univariate and multivariate analyses, are considered independent factors of PFS or OS, and they should indicate clinical significance. During the univariate and multivariate analyses, we also directly selected the upper limits of the normal clinical reference ranges as the cutoff values for comparisons among populations with different PFS and OS for analysis. For measurement data other than clinical laboratory parameters and without a normal reference range, such as pre-randomization maximal target lesion length and post-treatment granulocyte/lymphocyte ratio, the abovementioned ROC curve analysis was adopted to determine the cutoff values presenting the most significant differences in PFS or OS. To re-confirm the power of the parameters identified via multivariate analysis in predicting PFS or OS, we further divided the groups based on the cutoff values of each index, and the PFS and OS of the subgroups were calculated. The results validated that the differences in PFS or OS between the two subgroups were statistically significant. Therefore, selection of the abovementioned cutoff values was considered reasonable.

    Based on the results, the previous treatment has not been considered an independent factor. Previously reported factors that correlated with the development of tumor resistance (pre-treatment lines and types of treatment)showed no statistical significance in the univariate or multivariate analysis. Traditionally, it was believed that increased chemotherapeutic line triggered multidrug resistance (MDR) in the tumor cells6, resulting in resistance to multiple chemotherapy drugs. Therefore, the efficacy of the second-line regimen was considered to be inferior to the first-line regimen. EGFR-TKIs can also trigger T790 mutation and c-Met gene amplification, resulting in resistance to first-generation drugs8,9. However, results of the current study showed that the abovementioned factors did not affect the prognosis after anlotinib treatment. This was probably attributable to the fact that anlotinib has mechanisms of action that are completely independent of the previous therapeutic mechanisms that caused changes in molecules that are susceptible to drug resistance. That is, its efficacy was not affected by MDR induced by chemotherapy,and it still remained effective for c-Met gene amplification2induced by EGFR-TKI. Theoretically, increased therapeutic types and lines increased gene changes, thus indicating the possibility of resistance to any novel drug. However, our present study has not investigated the correlation between the gene mutation load10induced by different previous therapeutic lines and the efficacy of anlotinib or any molecular mechanisms that may induce resistance to anlotinib. Nevertheless, a pre-treatment total tumor load(sum of pre-randomization maximal target lesion length) >72 mm predicted poor PFS and OS in the univariate analysis and poor OS in the multivariate analysis, and this result still indicated that the efficacy of anlotinib may be suboptimal in larger tumors with greater heterogeneity and mutation load.Therefore, efforts should be made to promote anlotinib from third-line therapy to second- or first-line therapy for thetreatment of early tumors.

    Table 4 PFS and OS of each variable from the subgroups were divided on the basis of the cutoff values

    It was noteworthy that factors from the multivariate analysis caused changes in the body and metabolism of patients, and the resultant adverse events (up to seven events,such as post-treatment ECOG score as well as hypertension,hand–foot syndrome, and high blood glucose, triglyceride,TSH, and ALP levels, observed during the trial period)predominately affected efficacy and prognosis. This phenomenon indicated that multiple targets and broad signaling pathways covered by anlotinib could help overcome the acquired resistance induced by previous few-line treatments. However, compared to the mono-target agents, it may cause more adverse reactions in patients and interact with their internal environments. Thus, the level of efficacy of anlotinib was primarily dependent on the individual physical characteristics of the patients.

    Similar to EGFR-TKIs11, treatment with anlotinib also resulted in hand–foot syndrome, which was considered to be a predictor of good PFS. Meanwhile, similar to antiangiogenic targeting agents12, anlotinib caused hypertension and prolonged QT intervals, with the former considered a good predictor of PFS. From the perspective of adverse events,although they have been proven tolerable and transient,anlotinib simultaneously functioned as an antiangiogenic targeting and EGFR-TKI agent.

    In this study, post-treatment granulocyte/lymphocyte ratio has been considered a risk factor of both PFS and OS; hence,it deserves special attention. Studies conducted in China and other countries have shown that the tumor-free survival rate was shorter in patients with abnormally increased peripheral blood granulocyte levels during relapse after lung surgery than in patients with normal levels. Hence, the concept of“tumor-related leukocytosis” has been proposed13, which is a syndrome that occurs due to the absence of immune function and lack of lymphocytes. Sequential studies have further revealed that the patients’ percentage of CD8+ T cells was usually low, the CD4+/CD8+ T-cell ratio was high, and OS was short14. Although no specific immune-related parameters were detected in this trial, our current results strongly suggested that the efficacy of anlotinib was probably correlated with the post-treatment immune function status and response of the patient, which further indicated the need for special attention to the changes in immune parameters in future studies and the use of anlotinib and immuneenhancing therapy, which is similar to other assessments of TKI in this field15.

    Another notable result in our study was the elevated TSH levels and changes in metabolic parameters (including blood triglyceride and blood glucose levels) caused by anlotinib,which may be predictors of good prognosis, and elevated blood triglyceride levels protected both PFS and OS from the risk factors. Although such adverse events in the trial seldom reached grade III (3.06%, 0%), they covered a broad range.That is, the incidence rate of hypertriglyceridemia was 44.56% in the anlotinib group. However, it was only 23.78% in the placebo group. The incidence rates of hypercholesterolemia were 41.84% and 13.99%, respectively,and those of hyper-low density lipoproteinemia were 21.09%and 7.69%, respectively. However, the impact of small molecule targeted therapy on the endocrine system and fat metabolism are less assessed, and the results are usually contradictory. For instance, Ho et al.16have found that the levels of polyunsaturated fatty acids were elevated in patients with EGFR mutations, whereas reduced proportion of polyunsaturated fatty acids in the membrane phospholipids induced by inhibitors also lowered the activity of the EGFR membrane receptors, which shows a synergistic effect with gefitinib17. Other studies have also found that the mammalian target of sirolimus, which is a rapamycin(mTOR) inhibitor, increased the blood levels of total cholesterol and triglycerides18,19. Further studies have revealed that such result might be attributed to the fact that sirolimus reduced the activity of post-heparin lipoprotein lipase, which is the primary enzyme responsible for triglyceride metabolism, and this induces hypertriglyceridemia20. This result indicated that patients may often require adjuvant therapy with lipid-lowering drugs and that several indicators of lipid metabolism may be effective markers of small molecular targeted drugs. Future studies should focus on assessing the effects of anlotinib on the endocrine system and its subsequent potential effect on the immune and hematopoietic systems to identify the possible predictors of efficacy and prognosis. Yang et al.21from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Science have found that the inhibition of cholesterol esterification could enhance the antitumor activity of CD8+T cells (also known as killer T cells), indicating that such studies are strongly recommended.

    In conclusion, anlotinib plays a dual role as an antitumor and antiangiogenic agent. Its broad target range can help overcome the acquired resistance induced by multiple chemotherapies/targeted treatments. However, it is also more susceptible to interactions with the patient’s internal environment than mono-targeted agents. Factors, including tumor burden, gene characteristics, as well as a patient’s immune, endocrine, and metabolic status, may also affect the efficacy and prognosis of anlotinib treatment. Further indepth studies must be conducted to identify the reliable markers of efficacy and prognosis.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    亚洲精品国产成人久久av| 一夜夜www| 日产精品乱码卡一卡2卡三| 亚洲精品亚洲一区二区| 日本成人三级电影网站| 少妇高潮的动态图| 国产毛片a区久久久久| 久久久久免费精品人妻一区二区| 欧美日本视频| 成人永久免费在线观看视频| 国产成人午夜福利电影在线观看| 啦啦啦观看免费观看视频高清| 联通29元200g的流量卡| 99热这里只有是精品50| 国产在线精品亚洲第一网站| 国产久久久一区二区三区| 熟女人妻精品中文字幕| 最近手机中文字幕大全| 能在线免费看毛片的网站| 18禁在线无遮挡免费观看视频| 精品免费久久久久久久清纯| 国产一区二区三区在线臀色熟女| 亚洲18禁久久av| 久久精品国产清高在天天线| 一区福利在线观看| 国产精品久久久久久精品电影| 草草在线视频免费看| 亚洲av男天堂| 精品国产三级普通话版| 搡女人真爽免费视频火全软件| 精品人妻视频免费看| 日本与韩国留学比较| 在线观看av片永久免费下载| 久久精品91蜜桃| av.在线天堂| .国产精品久久| 亚洲第一区二区三区不卡| 一级黄色大片毛片| 国产白丝娇喘喷水9色精品| 免费av观看视频| 国产伦理片在线播放av一区 | 中出人妻视频一区二区| 少妇熟女欧美另类| 国内精品宾馆在线| 午夜免费激情av| 国产精华一区二区三区| 最后的刺客免费高清国语| 日韩高清综合在线| 插阴视频在线观看视频| 精品欧美国产一区二区三| 欧美色欧美亚洲另类二区| 麻豆乱淫一区二区| 蜜桃亚洲精品一区二区三区| 精品99又大又爽又粗少妇毛片| 直男gayav资源| 级片在线观看| 免费观看精品视频网站| 91精品一卡2卡3卡4卡| 国产亚洲精品av在线| 亚洲在久久综合| 在线a可以看的网站| 国产精品1区2区在线观看.| 在线观看66精品国产| 高清在线视频一区二区三区 | 欧美精品国产亚洲| 又粗又硬又长又爽又黄的视频 | 午夜福利在线观看吧| 午夜老司机福利剧场| 亚洲精品久久国产高清桃花| 男人的好看免费观看在线视频| 国产亚洲av嫩草精品影院| 一进一出抽搐动态| 日韩一区二区三区影片| 女人被狂操c到高潮| 99热这里只有精品一区| 久久精品国产亚洲av天美| 久久精品国产亚洲av天美| 国产精品麻豆人妻色哟哟久久 | 亚洲电影在线观看av| 边亲边吃奶的免费视频| av在线观看视频网站免费| 久久国产乱子免费精品| 少妇被粗大猛烈的视频| av免费在线看不卡| 国产精品,欧美在线| 久久久久久久久久黄片| 久久精品91蜜桃| 免费看光身美女| 色5月婷婷丁香| 亚洲欧美日韩高清在线视频| 日韩欧美国产在线观看| 给我免费播放毛片高清在线观看| 成人漫画全彩无遮挡| 国内少妇人妻偷人精品xxx网站| 大又大粗又爽又黄少妇毛片口| 99热这里只有是精品在线观看| 特大巨黑吊av在线直播| 色视频www国产| 亚洲一区高清亚洲精品| 一进一出抽搐动态| 在线免费十八禁| 最后的刺客免费高清国语| 亚洲精品粉嫩美女一区| 国产精品免费一区二区三区在线| 国产 一区精品| 欧美+亚洲+日韩+国产| av.在线天堂| 亚洲人成网站在线播放欧美日韩| 欧美不卡视频在线免费观看| 人人妻人人看人人澡| 精品久久久噜噜| 亚洲av成人精品一区久久| 国产91av在线免费观看| 99热这里只有是精品在线观看| 中国美女看黄片| 日韩强制内射视频| 熟女电影av网| 青春草视频在线免费观看| 亚洲欧美精品综合久久99| 精品无人区乱码1区二区| 亚洲人与动物交配视频| 美女cb高潮喷水在线观看| 狂野欧美激情性xxxx在线观看| 男女做爰动态图高潮gif福利片| 亚洲av第一区精品v没综合| 一区福利在线观看| 日韩成人伦理影院| 欧美极品一区二区三区四区| 中国国产av一级| 爱豆传媒免费全集在线观看| 国产真实伦视频高清在线观看| 三级国产精品欧美在线观看| 人人妻人人澡人人爽人人夜夜 | 99久久精品国产国产毛片| 天美传媒精品一区二区| 国产精品三级大全| 亚洲av中文av极速乱| 寂寞人妻少妇视频99o| 国产精品一区二区三区四区免费观看| 久久久久久久久久成人| av专区在线播放| 日本一本二区三区精品| 国产在线精品亚洲第一网站| 乱系列少妇在线播放| 性色avwww在线观看| 嫩草影院入口| 69av精品久久久久久| 爱豆传媒免费全集在线观看| av天堂在线播放| 国产亚洲5aaaaa淫片| 亚洲自拍偷在线| 少妇熟女aⅴ在线视频| 一级毛片aaaaaa免费看小| 国产色爽女视频免费观看| 亚洲精品乱码久久久v下载方式| 啦啦啦韩国在线观看视频| 99热这里只有精品一区| 国产精品久久电影中文字幕| 啦啦啦啦在线视频资源| 在线免费十八禁| 久久久国产成人免费| 国内精品宾馆在线| 女人十人毛片免费观看3o分钟| 久久久精品欧美日韩精品| 成年女人永久免费观看视频| 成人av在线播放网站| 亚洲七黄色美女视频| 两个人视频免费观看高清| 69av精品久久久久久| 一夜夜www| 国产高清有码在线观看视频| 在线观看美女被高潮喷水网站| 黄色视频,在线免费观看| 亚洲18禁久久av| 有码 亚洲区| 一边亲一边摸免费视频| 国产精品一区二区三区四区久久| 国产av不卡久久| 91狼人影院| 中国美白少妇内射xxxbb| 欧美激情国产日韩精品一区| 久久久久国产网址| 国产伦在线观看视频一区| 亚洲无线观看免费| av在线亚洲专区| 欧美日韩国产亚洲二区| 久久久欧美国产精品| 色5月婷婷丁香| 亚洲成人av在线免费| 亚洲人成网站在线播放欧美日韩| a级一级毛片免费在线观看| 国产精品人妻久久久久久| 国产熟女欧美一区二区| 悠悠久久av| 欧美高清成人免费视频www| 熟女电影av网| 成人亚洲欧美一区二区av| 变态另类成人亚洲欧美熟女| 波多野结衣高清无吗| 亚洲成人久久性| 免费看a级黄色片| 亚洲熟妇中文字幕五十中出| 中文精品一卡2卡3卡4更新| 国产精品一区二区三区四区久久| 国产成人福利小说| 狂野欧美激情性xxxx在线观看| 中文字幕熟女人妻在线| 成人午夜高清在线视频| 午夜福利在线观看吧| 偷拍熟女少妇极品色| 亚洲国产欧美人成| 国产精品人妻久久久影院| 国产男人的电影天堂91| 亚洲18禁久久av| 久久久久久国产a免费观看| 91久久精品国产一区二区三区| 九九热线精品视视频播放| 两个人视频免费观看高清| 久久精品综合一区二区三区| 嫩草影院入口| 好男人视频免费观看在线| 插阴视频在线观看视频| 美女cb高潮喷水在线观看| 在线免费观看不下载黄p国产| 国产人妻一区二区三区在| 麻豆国产av国片精品| 亚洲最大成人手机在线| 亚洲欧美日韩高清专用| 午夜激情福利司机影院| 久久草成人影院| 国产精品麻豆人妻色哟哟久久 | 99久久人妻综合| av黄色大香蕉| 日韩视频在线欧美| 99视频精品全部免费 在线| 国产精品一区二区性色av| av天堂在线播放| 国产不卡一卡二| 99热只有精品国产| 国产一区二区三区在线臀色熟女| av在线播放精品| 久久午夜福利片| 精品人妻熟女av久视频| 久久精品久久久久久久性| 国产69精品久久久久777片| 久久精品国产99精品国产亚洲性色| 久久国内精品自在自线图片| 在线免费十八禁| 免费观看的影片在线观看| 亚洲av电影不卡..在线观看| 乱码一卡2卡4卡精品| 一个人看视频在线观看www免费| 永久网站在线| eeuss影院久久| 国国产精品蜜臀av免费| 亚洲精品粉嫩美女一区| 久久综合国产亚洲精品| 免费搜索国产男女视频| 一个人免费在线观看电影| 97热精品久久久久久| 亚洲四区av| 国产精品美女特级片免费视频播放器| 日本撒尿小便嘘嘘汇集6| 久久精品久久久久久久性| 老师上课跳d突然被开到最大视频| 成人特级黄色片久久久久久久| 小说图片视频综合网站| 日韩欧美精品v在线| 嫩草影院精品99| 精品久久久久久久末码| 欧美成人精品欧美一级黄| 成人午夜精彩视频在线观看| 成人美女网站在线观看视频| 久久久国产成人精品二区| 亚洲av电影不卡..在线观看| 久久人妻av系列| 成人高潮视频无遮挡免费网站| 高清午夜精品一区二区三区 | 淫秽高清视频在线观看| 搡老妇女老女人老熟妇| 一本一本综合久久| 日韩欧美国产在线观看| 午夜视频国产福利| 三级经典国产精品| 女同久久另类99精品国产91| 3wmmmm亚洲av在线观看| 国产高清视频在线观看网站| 欧美一区二区亚洲| 久久99热6这里只有精品| 久久精品国产99精品国产亚洲性色| 联通29元200g的流量卡| 亚洲国产高清在线一区二区三| 国产av在哪里看| 高清日韩中文字幕在线| 综合色av麻豆| 男女视频在线观看网站免费| 久久久久网色| 国产又黄又爽又无遮挡在线| 亚洲人成网站在线观看播放| 老熟妇乱子伦视频在线观看| 悠悠久久av| 哪个播放器可以免费观看大片| 黄色视频,在线免费观看| 一本久久精品| 成人二区视频| 别揉我奶头 嗯啊视频| .国产精品久久| 亚洲精品自拍成人| 久久99热这里只有精品18| 精品久久久久久久久av| 99热网站在线观看| 亚洲精品国产成人久久av| 成人性生交大片免费视频hd| 欧美另类亚洲清纯唯美| 成人欧美大片| 亚洲经典国产精华液单| 欧美+亚洲+日韩+国产| 日产精品乱码卡一卡2卡三| 中文字幕熟女人妻在线| 亚洲婷婷狠狠爱综合网| 国产麻豆成人av免费视频| 精品人妻一区二区三区麻豆| 国产乱人偷精品视频| 看片在线看免费视频| 国产高潮美女av| 亚洲美女视频黄频| 色哟哟·www| 国产成人a∨麻豆精品| 久久人人爽人人片av| 一卡2卡三卡四卡精品乱码亚洲| 国产精品麻豆人妻色哟哟久久 | 亚洲精华国产精华液的使用体验 | 婷婷色综合大香蕉| av免费在线看不卡| 久久久久久伊人网av| 99九九线精品视频在线观看视频| 亚洲va在线va天堂va国产| 美女高潮的动态| 高清毛片免费看| 亚洲国产高清在线一区二区三| 2021天堂中文幕一二区在线观| 免费不卡的大黄色大毛片视频在线观看 | 青春草视频在线免费观看| 亚洲国产精品合色在线| 欧美一区二区精品小视频在线| 看非洲黑人一级黄片| 久久精品国产清高在天天线| 一级毛片电影观看 | 国产白丝娇喘喷水9色精品| 91久久精品电影网| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 日本黄色片子视频| 日本三级黄在线观看| 91精品一卡2卡3卡4卡| 成年女人看的毛片在线观看| 亚洲精品日韩av片在线观看| 亚洲av.av天堂| 超碰av人人做人人爽久久| 99在线视频只有这里精品首页| 亚洲国产精品久久男人天堂| 日韩成人伦理影院| 亚洲一区二区三区色噜噜| 少妇丰满av| 最后的刺客免费高清国语| 人妻久久中文字幕网| 日韩在线高清观看一区二区三区| 精品不卡国产一区二区三区| 91av网一区二区| av卡一久久| 天堂网av新在线| ponron亚洲| 少妇丰满av| 亚洲精品国产成人久久av| 成人无遮挡网站| 国产精品蜜桃在线观看 | av天堂中文字幕网| 男女啪啪激烈高潮av片| 精品午夜福利在线看| 精品久久久久久久末码| 极品教师在线视频| 国产伦理片在线播放av一区 | 人体艺术视频欧美日本| 男的添女的下面高潮视频| 日韩欧美一区二区三区在线观看| 免费观看人在逋| 中文字幕精品亚洲无线码一区| 真实男女啪啪啪动态图| 日日摸夜夜添夜夜添av毛片| 国产成人精品久久久久久| 国国产精品蜜臀av免费| 男人和女人高潮做爰伦理| 久久久久久久久久久丰满| 国产精品一区二区三区四区免费观看| 国产高潮美女av| 国产一区亚洲一区在线观看| 精品人妻熟女av久视频| 午夜久久久久精精品| 伦理电影大哥的女人| 老熟妇乱子伦视频在线观看| 精品少妇黑人巨大在线播放 | 51国产日韩欧美| 亚洲国产精品国产精品| 久久鲁丝午夜福利片| 99国产极品粉嫩在线观看| 国产成人精品婷婷| 国产成人a∨麻豆精品| 老司机福利观看| 国产av麻豆久久久久久久| 波多野结衣高清无吗| 国产国拍精品亚洲av在线观看| 欧美成人一区二区免费高清观看| 亚洲一区高清亚洲精品| 亚洲国产日韩欧美精品在线观看| 在线观看66精品国产| 婷婷色综合大香蕉| 国产亚洲精品久久久com| 乱码一卡2卡4卡精品| 变态另类成人亚洲欧美熟女| 国产不卡一卡二| 一级毛片我不卡| av在线亚洲专区| 深夜a级毛片| 久久精品综合一区二区三区| 成熟少妇高潮喷水视频| 免费看光身美女| 国产精品无大码| 国产精品久久久久久av不卡| 亚洲人成网站在线播| 在线播放无遮挡| 国产成人91sexporn| 日韩高清综合在线| 校园春色视频在线观看| 夜夜看夜夜爽夜夜摸| 国产成年人精品一区二区| 能在线免费看毛片的网站| 在线国产一区二区在线| 国产亚洲5aaaaa淫片| 中国美女看黄片| 精品久久久久久久久久久久久| 在线天堂最新版资源| 欧美性猛交黑人性爽| 最近2019中文字幕mv第一页| 免费人成在线观看视频色| www日本黄色视频网| 天美传媒精品一区二区| 国产单亲对白刺激| 永久网站在线| 亚洲国产欧美在线一区| 日本av手机在线免费观看| 中文字幕久久专区| 亚洲欧美精品自产自拍| 欧美精品国产亚洲| 国产老妇伦熟女老妇高清| 日韩视频在线欧美| 成人毛片60女人毛片免费| 91久久精品国产一区二区成人| 蜜桃久久精品国产亚洲av| 人妻制服诱惑在线中文字幕| a级毛片a级免费在线| 中文字幕av成人在线电影| 91久久精品国产一区二区三区| 亚洲欧美中文字幕日韩二区| 国产探花在线观看一区二区| 国产熟女欧美一区二区| 搡女人真爽免费视频火全软件| 国产一区二区亚洲精品在线观看| 久99久视频精品免费| 18+在线观看网站| 日日啪夜夜撸| 超碰av人人做人人爽久久| 性欧美人与动物交配| 亚洲人成网站在线观看播放| 国产精品久久久久久亚洲av鲁大| 99久久无色码亚洲精品果冻| 精品久久久久久成人av| 免费无遮挡裸体视频| 伦理电影大哥的女人| 欧美精品一区二区大全| 国产精品日韩av在线免费观看| 午夜激情福利司机影院| 久久久久久久久久成人| 精品午夜福利在线看| 在线免费十八禁| 午夜视频国产福利| 日本黄大片高清| 欧美zozozo另类| 中文字幕免费在线视频6| 在线观看免费视频日本深夜| 九色成人免费人妻av| 国产精品一区www在线观看| a级一级毛片免费在线观看| 国产三级中文精品| 又粗又硬又长又爽又黄的视频 | 能在线免费观看的黄片| а√天堂www在线а√下载| 国产成人精品一,二区 | 少妇高潮的动态图| 嘟嘟电影网在线观看| 深爱激情五月婷婷| 成年女人看的毛片在线观看| 性欧美人与动物交配| 一本一本综合久久| 国内精品久久久久精免费| 中文亚洲av片在线观看爽| 亚州av有码| 精品人妻熟女av久视频| 欧美区成人在线视频| 99热只有精品国产| 麻豆精品久久久久久蜜桃| 亚洲欧美日韩东京热| 国产 一区精品| 搡老妇女老女人老熟妇| 晚上一个人看的免费电影| 国产老妇女一区| 精品久久久久久久久av| 国产淫片久久久久久久久| 亚洲丝袜综合中文字幕| 国产精品免费一区二区三区在线| 国产真实乱freesex| 国产精品99久久久久久久久| 少妇丰满av| 久久久色成人| 熟女电影av网| 丰满乱子伦码专区| 欧美另类亚洲清纯唯美| 夜夜看夜夜爽夜夜摸| 99热只有精品国产| 亚洲不卡免费看| 色哟哟哟哟哟哟| 搡老妇女老女人老熟妇| 一进一出抽搐动态| 精品熟女少妇av免费看| a级毛片免费高清观看在线播放| 狂野欧美白嫩少妇大欣赏| 亚洲最大成人中文| 波多野结衣高清作品| 天堂影院成人在线观看| 日韩精品青青久久久久久| 91久久精品国产一区二区成人| 国产日韩欧美在线精品| 日韩一本色道免费dvd| 亚洲av免费高清在线观看| 国产午夜精品一二区理论片| 婷婷色综合大香蕉| 日本欧美国产在线视频| 中国美白少妇内射xxxbb| 日韩欧美精品v在线| 日韩高清综合在线| 18+在线观看网站| 午夜a级毛片| 欧美色视频一区免费| 天堂中文最新版在线下载 | 久久综合国产亚洲精品| 国产精华一区二区三区| 精品久久久久久久人妻蜜臀av| 亚洲国产欧洲综合997久久,| 成人鲁丝片一二三区免费| 欧美日韩一区二区视频在线观看视频在线 | 99热这里只有是精品50| 欧美精品一区二区大全| 美女xxoo啪啪120秒动态图| 久久久久久久久中文| 国产一区二区在线观看日韩| 日韩亚洲欧美综合| 国产午夜福利久久久久久| 99九九线精品视频在线观看视频| 中出人妻视频一区二区| 91aial.com中文字幕在线观看| 亚洲五月天丁香| 欧美潮喷喷水| 国产国拍精品亚洲av在线观看| 中文字幕免费在线视频6| 国产不卡一卡二| 一本一本综合久久| 久久久久免费精品人妻一区二区| 91久久精品国产一区二区三区| 亚洲av电影不卡..在线观看| 全区人妻精品视频| 亚洲欧美清纯卡通| 熟妇人妻久久中文字幕3abv| 日韩精品有码人妻一区| 午夜福利在线观看吧| 赤兔流量卡办理| 中文精品一卡2卡3卡4更新| 麻豆av噜噜一区二区三区| 大香蕉久久网| 国产黄a三级三级三级人| 成人鲁丝片一二三区免费| 三级男女做爰猛烈吃奶摸视频| 日本与韩国留学比较| 一本久久精品| 亚洲中文字幕日韩| 久久综合国产亚洲精品| 国产av麻豆久久久久久久| 亚洲内射少妇av| 成人亚洲精品av一区二区| 12—13女人毛片做爰片一| 校园人妻丝袜中文字幕| 一级毛片aaaaaa免费看小| 精品久久久久久久久亚洲| 精品99又大又爽又粗少妇毛片| 久久热精品热| 亚洲成a人片在线一区二区| 美女大奶头视频| 日本三级黄在线观看| 我的女老师完整版在线观看| 亚洲在线自拍视频| 九九热线精品视视频播放| 亚洲,欧美,日韩| 色播亚洲综合网| 日本成人三级电影网站| 毛片女人毛片| 亚洲av中文av极速乱| 蜜桃亚洲精品一区二区三区| 国产蜜桃级精品一区二区三区|